Insider Buying: Ascendis Pharma A/S (NASDAQ:ASND) Director Purchases $95,120.00 in Stock

Ascendis Pharma A/S (NASDAQ:ASND) Director Jean Jacques Bienaime acquired 400 shares of the stock in a transaction dated Tuesday, May 26th. The stock was acquired at an average price of $237.80 per share, with a total value of $95,120.00. Following the completion of the acquisition, the director owned 400 shares in the company, valued at approximately $95,120. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Ascendis Pharma A/S Trading Down 5.6%

Shares of ASND opened at $224.11 on Friday. The firm has a market cap of $13.98 billion, a price-to-earnings ratio of 25.85 and a beta of 0.41. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.72 and a current ratio of 1.00. Ascendis Pharma A/S has a fifty-two week low of $158.16 and a fifty-two week high of $250.74. The firm has a 50 day moving average price of $233.52 and a 200-day moving average price of $223.08.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.11. The business had revenue of $285.45 million during the quarter, compared to the consensus estimate of $362.47 million. As a group, equities research analysts forecast that Ascendis Pharma A/S will post 11.73 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ASND. Wolfe Research restated an “outperform” rating and issued a $260.00 price objective on shares of Ascendis Pharma A/S in a report on Monday, March 2nd. Evercore restated an “outperform” rating and issued a $329.00 price objective on shares of Ascendis Pharma A/S in a report on Friday, May 15th. Royal Bank Of Canada boosted their price objective on shares of Ascendis Pharma A/S from $250.00 to $275.00 and gave the stock an “outperform” rating in a report on Monday, March 2nd. Wells Fargo & Company lowered their price objective on shares of Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Finally, Bank of America lifted their target price on shares of Ascendis Pharma A/S from $262.00 to $292.00 and gave the stock a “buy” rating in a research note on Thursday, April 16th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $295.39.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Rhumbline Advisers boosted its stake in Ascendis Pharma A/S by 4.0% in the 2nd quarter. Rhumbline Advisers now owns 1,441 shares of the biotechnology company’s stock worth $249,000 after purchasing an additional 55 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Ascendis Pharma A/S by 1.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,081 shares of the biotechnology company’s stock worth $1,209,000 after purchasing an additional 58 shares in the last quarter. Certuity LLC boosted its stake in Ascendis Pharma A/S by 5.7% in the 4th quarter. Certuity LLC now owns 1,170 shares of the biotechnology company’s stock worth $249,000 after purchasing an additional 63 shares in the last quarter. Personal CFO Solutions LLC boosted its stake in Ascendis Pharma A/S by 4.4% in the 1st quarter. Personal CFO Solutions LLC now owns 1,519 shares of the biotechnology company’s stock worth $347,000 after purchasing an additional 64 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its stake in Ascendis Pharma A/S by 34.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 69 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.